Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress

M. Tomandlova, J. Jarkovsky, J. Tomandl, L. Kubkova, P. Kala, S. Littnerova, J. Gottwaldova, P. Kubena, E. Ganovska, M. Poloczek, J. Spinar, C. Mueller, A. Mebazaa, M. Pavkova Goldbergova, J. Parenica,

. 2015 ; 2015 (-) : 159051. [pub] 20150401

Language English Country United States

Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16000159

OBJECTIVE: Pentraxin-3 (PTX3) appears to have a cardioprotective effect through a positive influence against postreperfusion damage. This study assesses the prognostic value of PTX3 level and its relationship with clinical parameters and markers of oxidative stress and nitric oxide metabolism in patients with ST-elevation myocardial infarction (STEMI). METHODS: Plasma/serum levels of several biomarkers of inflammation and oxidative stress and nitrite/nitrate were assessed upon admission and 24 h after STEMI onset in patients treated by primary percutaneous coronary intervention. RESULTS: ROC analysis showed that plasma PTX3 at 24 h was a strong predictor of 30-day and 1-year mortality and independent predictor of combined end-point of left ventricle dysfunction or mortality in 1 year. The inflammatory response expressed by PTX3 had a significant relationship with age, heart failure, infarct size, impaired flow in the infarct-related artery, and renal function and positively correlated with neopterin, TNF-α, 8-hydroxy-2'-deoxyguanosine, and nitrite/nitrate. CONCLUSIONS: Plasma PTX3 at 24 h after STEMI onset is a strong predictor of 30-day and 1-year mortality. PTX3 as a single biomarker is comparable with currently used scoring systems (TIMI or GRACE) or B-type natriuretic peptide. PTX3 is also an independent predictor of combined end-point of left ventricle dysfunction or mortality in 1 year.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000159
003      
CZ-PrNML
005      
20200121084348.0
007      
ta
008      
160108s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2015/159051 $2 doi
035    __
$a (PubMed)25922551
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tomandlova, Marie $u Department of Biochemistry, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
245    10
$a Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress / $c M. Tomandlova, J. Jarkovsky, J. Tomandl, L. Kubkova, P. Kala, S. Littnerova, J. Gottwaldova, P. Kubena, E. Ganovska, M. Poloczek, J. Spinar, C. Mueller, A. Mebazaa, M. Pavkova Goldbergova, J. Parenica,
520    9_
$a OBJECTIVE: Pentraxin-3 (PTX3) appears to have a cardioprotective effect through a positive influence against postreperfusion damage. This study assesses the prognostic value of PTX3 level and its relationship with clinical parameters and markers of oxidative stress and nitric oxide metabolism in patients with ST-elevation myocardial infarction (STEMI). METHODS: Plasma/serum levels of several biomarkers of inflammation and oxidative stress and nitrite/nitrate were assessed upon admission and 24 h after STEMI onset in patients treated by primary percutaneous coronary intervention. RESULTS: ROC analysis showed that plasma PTX3 at 24 h was a strong predictor of 30-day and 1-year mortality and independent predictor of combined end-point of left ventricle dysfunction or mortality in 1 year. The inflammatory response expressed by PTX3 had a significant relationship with age, heart failure, infarct size, impaired flow in the infarct-related artery, and renal function and positively correlated with neopterin, TNF-α, 8-hydroxy-2'-deoxyguanosine, and nitrite/nitrate. CONCLUSIONS: Plasma PTX3 at 24 h after STEMI onset is a strong predictor of 30-day and 1-year mortality. PTX3 as a single biomarker is comparable with currently used scoring systems (TIMI or GRACE) or B-type natriuretic peptide. PTX3 is also an independent predictor of combined end-point of left ventricle dysfunction or mortality in 1 year.
650    _2
$a senioři $7 D000368
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a C-reaktivní protein $x metabolismus $7 D002097
650    _2
$a deoxyguanosin $x analogy a deriváty $x krev $7 D003849
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční selhání $x krev $x mortalita $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a infarkt myokardu $x krev $x mortalita $7 D009203
650    _2
$a natriuretický peptid typu B $x krev $7 D020097
650    _2
$a neopterin $x krev $7 D019798
650    _2
$a dusitany $x krev $7 D009573
650    12
$a oxidační stres $7 D018384
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a sérový amyloidový protein $x metabolismus $7 D000683
650    _2
$a troponin I $x krev $7 D019210
650    _2
$a TNF-alfa $x krev $7 D014409
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Tomandl, Josef $u Department of Biochemistry, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Kubkova, Lenka $u Department of Cardiovascular Disease, International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic ; Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Kala, Petr $u Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Littnerova, Simona $u Institute of Biostatistics and Analyses, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Gottwaldova, Jana $u Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic ; Department of Biochemistry, University Hospital Brno, 625 00 Brno, Czech Republic.
700    1_
$a Kubena, Petr $u Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Ganovska, Eva $u Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Poloczek, Martin $u Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Spinar, Jindrich $u Department of Cardiovascular Disease, International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic ; Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Mueller, Christian $u Department of Internal Medicine, University Hospital, 4031 Basel, Switzerland.
700    1_
$a Mebazaa, Alexandre $u Department of Anesthesiology and Critical Care Medicine, Saint Luis Lariboisière University Hospital, 75475 Paris, France ; Cardiac Diseases and Biomarkers, INSERM UMR 942, Saint Luis Lariboisière University Hospital, 75475 Paris, France.
700    1_
$a Pavkova Goldbergova, Monika $u Institute of Pathological Physiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Parenica, Jiri $u Department of Cardiovascular Disease, International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic ; Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
773    0_
$w MED00001413 $t Disease markers $x 1875-8630 $g Roč. 2015, č. - (2015), s. 159051
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25922551 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20200121084725 $b ABA008
999    __
$a ok $b bmc $g 1102440 $s 924365
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 2015 $c - $d 159051 $e 20150401 $i 1875-8630 $m Disease markers $n Dis Markers $x MED00001413
LZP    __
$a Pubmed-20160108

Find record

Citation metrics

Archiving options